Journal of the Korean Association of Oral and Maxillofacial Surgeons

The Korean Association of Oral and Maxillofacial Surgeons (대한구강악안면외과학회)
권호 표지
DOI QR코드

DOI QR Code

Primary malignant mucosal melanoma of the maxillofacial area

  • Kim, Hyounmin (Department of Oral and Maxillofacial Surgery, Yonsei University College of Dentistry) ;
  • Lee, Sanghoon (Oral Oncology Clinic, Research Institute and Hospital, National Cancer Center) ;
  • Cha, In-Ho (Department of Oral and Maxillofacial Surgery, Yonsei University College of Dentistry) ;
  • Kim, Hyung Jun (Department of Oral and Maxillofacial Surgery, Yonsei University College of Dentistry) ;
  • Nam, Woong (Department of Oral and Maxillofacial Surgery, Yonsei University College of Dentistry)
  • Received : 2020.10.14
  • Accepted : 2020.12.28
  • Published : 2021.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: We aimed to collect and report data from all patients who have been diagnosed with mucosal malignant melanoma to obtain the epidemiology and principles of current treatments. Materials and Methods: Between January 2008 and December 2018, 20 patients underwent surgery or follow-up observations at Yonsei University Dental Hospital. The patients' clinical information was reviewed retrospectively. Results: Seventeen of 20 patients had undergone definitive surgery, while only 6 patients received adjuvant radiotherapy or systemic therapy. Eight of 20 patients, including those that had recurrent lesions, were provided immunotherapy. The 3-year survival for all stages was 50%, with a local recurrence rate of 75% and a metastasis rate of 65%. Conclusion: The overall survival of patients receiving surgical treatment was longer than that of patients who did not undergo surgical resection. Eight of 20 patients received immunotherapy as the first-line regimen at our clinic, and those patients exhibited longer overall survival compared to patients in reported keynote studies.

Keywords

References

  1. Andersen LJ, Berthelsen A, Hansen HS. Malignant melanoma of the upper respiratory tract and the oral cavity. J Otolaryngol 1992;21:180-5.
  2. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998;83:1664-78. https://doi.org/10.1002/(sici)1097-0142(19981015)83:8<1664::aid-cncr23>3.0.co;2-g
  3. Yde SS, Sjoegren P, Heje M, Stolle LB. Mucosal melanoma: a literature review. Curr Oncol Rep 2018;20:28. https://doi.org/10.1007/s11912-018-0675-0
  4. Lund VJ, Howard DJ, Harding L, Wei WI. Management options and survival in malignant melanoma of the sinonasal mucosa. Laryngoscope 1999;109(2 Pt 1):208-11. https://doi.org/10.1097/00005537-199902000-00007
  5. Sapp JP, Eversole LR, Wysocki GP. Contemporary oral and maxillofacial pathology. 2nd ed. St. Louis: Mosby; 2004.
  6. Sun S, Huang X, Gao L, Zhang Y, Luo J, Zhang S, et al. Long-term treatment outcomes and prognosis of mucosal melanoma of the head and neck: 161 cases from a single institution. Oral Oncol 2017;74:115-22. https://doi.org/10.1016/j.oraloncology.2017.09.020
  7. Napierala MJ, Czarnecka AM. Mucosal melanoma - clinical presentation and treatment based on a case series. Oncol Clin Pract 2019;15:223-30. https://doi.org/10.5603/OCP.2019.0001
  8. Wu AJ, Gomez J, Zhung JE, Chan K, Gomez DR, Wolden SL, et al. Radiotherapy after surgical resection for head and neck mucosal melanoma. Am J Clin Oncol 2010;33:281-5. https://doi.org/10.1097/COC.0b013e3181a879f5
  9. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: head and neck cancers. Plymouth Meeting: NCCN; 2020:83-7.
  10. Mendenhall WM, Amdur RJ, Hinerman RW, Werning JW, Villaret DB, Mendenhall NP. Head and neck mucosal melanoma. Am J Clin Oncol 2005;28:626-30. https://doi.org/10.1097/01.coc.0000170805.14058.d3
  11. Lopez F, Rodrigo JP, Cardesa A, Triantafyllou A, Devaney KO, Mendenhall WM, et al. Update on primary head and neck mucosal melanoma. Head Neck 2016;38:147-55. https://doi.org/10.1002/hed.23872
  12. Gilligan D, Slevin NJ. Radical radiotherapy for 28 cases of mucosal melanoma in the nasal cavity and sinuses. Br J Radiol 1991;64:1147-50. https://doi.org/10.1259/0007-1285-64-768-1147
  13. Bartell HL, Bedikian AY, Papadopoulos NE, Dett TK, Ballo MT, Myers JN, et al. Biochemotherapy in patients with advanced head and neck mucosal melanoma. Head Neck 2008;30:1592-8. https://doi.org/10.1002/hed.20910
  14. Manolidis S, Donald PJ. Malignant mucosal melanoma of the head and neck: review of the literature and report of 14 patients. Cancer 1997;80:1373-86. https://doi.org/10.1002/(sici)1097-0142(19971015)80:8<1373::aid-cncr3>3.0.co;2-g
  15. Lazarev S, Gupta V, Hu K, Harrison LB, Bakst R. Mucosal melanoma of the head and neck: a systematic review of the literature. Int J Radiat Oncol Biol Phys 2014;90:1108-18. https://doi.org/10.1016/j.ijrobp.2014.03.042
  16. Bachar G, Loh KS, O'Sullivan B, Goldstein D, Wood S, Brown D, et al. Mucosal melanomas of the head and neck: experience of the Princess Margaret Hospital. Head Neck 2008;30:1325-31. https://doi.org/10.1002/hed.20878
  17. Martin JM, Porceddu S, Weih L, Corry J, Peters LJ. Outcomes in sinonasal mucosal melanoma. ANZ J Surg 2004;74:838-42. https://doi.org/10.1111/j.1445-1433.2004.03185.x
  18. Jethanamest D, Vila PM, Sikora AG, Morris LG. Predictors of survival in mucosal melanoma of the head and neck. Ann Surg Oncol 2011;18:2748-56. https://doi.org/10.1245/s10434-011-1685-4
  19. Moya-Plana A, Herrera Gomez RG, Rossoni C, Dercle L, Ammari S, Girault I, et al. Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma. Cancer Immunol Immunother 2019;68:1171-8. https://doi.org/10.1007/s00262-019-02351-7
  20. Hamid O, Robert C, Ribas A, Hodi FS, Walpole E, Daud A, et al. Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. Br J Cancer 2018;119:670-4. https://doi.org/10.1038/s41416-018-0207-6
  21. Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al.; CheckMate 238 Collaborators. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 2017;377:1824-35. https://doi.org/10.1056/NEJMoa1709030
  22. Si L, Zhang X, Shu Y, Pan H, Wu D, Liu J, et al. A phase Ib study of pembrolizumab as second-line therapy for Chinese patients with advanced or metastatic melanoma (KEYNOTE-151). Transl Oncol 2019;12:828-35. https://doi.org/10.1016/j.tranon.2019.02.007
  23. Manton T, Tillman B, McHugh J, Bellile E, McLean S, McKean E. Sinonasal melanoma: a single institutional analysis and future directions. J Neurol Surg B Skull Base 2019;80:484-92. https://doi.org/10.1055/s-0038-1676355